Abstract
Patients with haematological conditions have been disproportionately affected by the COVID-19 pandemic. A pooled meta-analysis of 3377 predominantly hospitalised patients with haematological malignancies and COVID-19 reported a mortality rate of 34% (95% CI 28–39). Advanced age (≥60 years) and non-White race were identified as risk factors for death. Mortality rate varied on the basis of the type of malignancy: 53% of patients with acquired bone marrow failure syndromes, 41% of patients with acute leukaemias, 32% of patients with lymphomas, 31% of patients with chronic lymphocytic leukaemia, and 34% of patients with myeloproliferative neoplasms.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
